Literature DB >> 18227430

Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation.

William J Metzler1, Joseph Yanchunas, Carolyn Weigelt, Kevin Kish, Herbert E Klei, Dianlin Xie, Yaqun Zhang, Martin Corbett, James K Tamura, Bin He, Lawrence G Hamann, Mark S Kirby, Jovita Marcinkeviciene.   

Abstract

The inhibition of DPP-IV by saxagliptin has been proposed to occur through formation of a covalent but reversible complex. To evaluate further the mechanism of inhibition, we determined the X-ray crystal structure of the DPP-IV:saxagliptin complex. This structure reveals covalent attachment between S630 and the inhibitor nitrile carbon (C-O distance <1.3 A). To investigate whether this serine addition is assisted by the catalytic His-Asp dyad, we generated two mutants of DPP-IV, S630A and H740Q, and assayed them for ability to bind inhibitor. DPP-IV H740Q bound saxagliptin with an approximately 1000-fold reduction in affinity relative to DPP-IV WT, while DPP-IV S630A showed no evidence for binding inhibitor. An analog of saxagliptin lacking the nitrile group showed unchanged binding properties to the both mutant proteins, highlighting the essential role S630 and H740 play in covalent bond formation between S630 and saxagliptin. Further supporting mechanism-based inhibition by saxagliptin, NMR spectra of enzyme-saxagliptin complexes revealed the presence of three downfield resonances with low fractionation factors characteristic of short and strong hydrogen bonds (SSHB). Comparison of the NMR spectra of various wild-type and mutant DPP-IV:ligand complexes enabled assignment of a resonance at approximately 14 ppm to H740. Two additional DPP-IV mutants, Y547F and Y547Q, generated to probe potential stabilization of the enzyme-inhibitor complex by this residue, did not show any differences in inhibitor binding either by ITC or NMR. Together with the previously published enzymatic data, the structural and binding data presented here strongly support a histidine-assisted covalent bond formation between S630 hydroxyl oxygen and the nitrile group of saxagliptin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227430      PMCID: PMC2222712          DOI: 10.1110/ps.073253208

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  24 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Decrypting the biochemical function of an essential gene from Streptococcus pneumoniae using ThermoFluor technology.

Authors:  Theodore E Carver; Brian Bordeau; Maxwell D Cummings; Eugene C Petrella; Michael J Pucci; Laura E Zawadzke; Brian A Dougherty; Jeffrey A Tredup; James W Bryson; Joseph Yanchunas; Michael L Doyle; Mark R Witmer; Marina I Nelen; Renee L DesJarlais; Edward P Jaeger; Heather Devine; Eric D Asel; Barry A Springer; Roger Bone; F Raymond Salemme; Matthew J Todd
Journal:  J Biol Chem       Date:  2005-01-05       Impact factor: 5.157

3.  Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118).

Authors:  Young B Kim; Lisa M Kopcho; Mark S Kirby; Lawrence G Hamann; Carolyn A Weigelt; William J Metzler; Jovita Marcinkeviciene
Journal:  Arch Biochem Biophys       Date:  2005-12-05       Impact factor: 4.013

4.  Crystallography & NMR system: A new software suite for macromolecular structure determination.

Authors:  A T Brünger; P D Adams; G M Clore; W L DeLano; P Gros; R W Grosse-Kunstleve; J S Jiang; J Kuszewski; M Nilges; N S Pannu; R J Read; L M Rice; T Simonson; G L Warren
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-09-01

5.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog.

Authors:  Hanne B Rasmussen; Sven Branner; Finn C Wiberg; Nicolai Wagtmann
Journal:  Nat Struct Biol       Date:  2003-01

6.  A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond.

Authors:  C S Cassidy; J Lin; P A Frey
Journal:  Biochemistry       Date:  1997-04-15       Impact factor: 3.162

7.  Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

Authors:  Bo Ahrén; Giovanni Pacini; James E Foley; Anja Schweizer
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

8.  Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.

Authors:  A M Lambeir; P Proost; C Durinx; G Bal; K Senten; K Augustyns; S Scharpé; J Van Damme; I De Meester
Journal:  J Biol Chem       Date:  2001-06-04       Impact factor: 5.157

9.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

10.  Fractionation factors and activation energies for exchange of the low barrier hydrogen bonding proton in peptidyl trifluoromethyl ketone complexes of chymotrypsin.

Authors:  J Lin; W M Westler; W W Cleland; J L Markley; P A Frey
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

View more
  17 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

Review 3.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

4.  Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.

Authors:  Seiichi Tanaka; Kunihiro Suzuki; Chie Aoki; Mai Niitani; Kanako Kato; Takanori Tomotsune; Yoshimasa Aso
Journal:  Diabetes Technol Ther       Date:  2014-08-21       Impact factor: 6.118

5.  The contribution of Tannerella forsythia dipeptidyl aminopeptidase IV in the breakdown of collagen.

Authors:  Susan Yost; Ana E Duran-Pinedo
Journal:  Mol Oral Microbiol       Date:  2018-10-05       Impact factor: 3.563

6.  New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.

Authors:  Baptist Gallwitz
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-10       Impact factor: 3.168

7.  Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis.

Authors:  Shyam Krishnan; Rand M Miller; Boxue Tian; R Dyche Mullins; Matthew P Jacobson; Jack Taunton
Journal:  J Am Chem Soc       Date:  2014-09-02       Impact factor: 15.419

8.  Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor.

Authors:  Hiroyuki Nojima; Kazuhiko Kanou; Genki Terashi; Mayuko Takeda-Shitaka; Gaku Inoue; Koichiro Atsuda; Chihiro Itoh; Chie Iguchi; Hajime Matsubara
Journal:  BMC Struct Biol       Date:  2016-08-05

9.  Investigation of Chlorella pyrenoidosa Protein as a Source of Novel Angiotensin I-Converting Enzyme (ACE) and Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides.

Authors:  Yuchen Li; Gilda Aiello; Enrico Mario Alessandro Fassi; Giovanna Boschin; Martina Bartolomei; Carlotta Bollati; Gabriella Roda; Anna Arnoldi; Giovanni Grazioso; Carmen Lammi
Journal:  Nutrients       Date:  2021-05-12       Impact factor: 5.717

10.  Navigating the chemical space of dipeptidyl peptidase-4 inhibitors.

Authors:  Watshara Shoombuatong; Veda Prachayasittikul; Nuttapat Anuwongcharoen; Napat Songtawee; Teerawat Monnor; Supaluk Prachayasittikul; Virapong Prachayasittikul; Chanin Nantasenamat
Journal:  Drug Des Devel Ther       Date:  2015-08-10       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.